financing

News

RYSE’s $50m digital health fund makes first investment

UK healthcare investor RYSE Asset Management has closed a new fund to support start-ups involved in digital health and care technologies, raising $50 million.

News

RNA therapy firm Avidity files $400m placement

Avidity Biosciences has filed a private placement worth around $400 million, seeking a cash infusion to help advance its pipeline of clinical-stage candidates that combine

News

University of Southampton scientist Prof Ali Tavassoli, who is Curve's chief scientific officer

UK biotech Curve swings £40.5m in Pfizer-backed round

Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree

R&D

The opportunities and challenges facing rare disease therapi...

To mark upcoming Rare Disease Day, pharmaphorum asked a panel of experts to give their thoughts on the opportunities and challenges facing developers of rare disease therapies in 2024.

News

Prof Jean-Phillipe Vert, Owkin's chief R&D officer

Bioptimus born with $35m for a foundation model for biology

A team of scientists formerly working at Google DeepMind and Owkin have joined forces to create Bioptimus, a start-up that will apply generative artificial intelligence (G

News

Freenome raises $254m for cancer tests, and other financings

Our round-up of recent biotech financings is headed by a $254 million private financing for cancer blood test specialist Freenome, with sizeable rounds for Cogent Bioscien

RYSE’s $50m digital health fund makes first investment

RNA therapy firm Avidity files $400m placement

UK biotech Curve swings £40.5m in Pfizer-backed round

The opportunities and challenges facing rare disease therapi...

Bioptimus born with $35m for a foundation model for biology

Freenome raises $254m for cancer tests, and other financings

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

financing

Editor's Picks